Apigenin and chrysin differ by exactly one atom arrangement: a single hydroxyl group on the B-ring. Chrysin is 5,7-dihydroxyflavone. Apigenin is 4′,5,7-trihydroxyflavone, chrysin plus one hydroxyl at the 4′ position. They are sister compounds in the truest chemical sense, they overlap in several biological actions, and they have arrived at completely different reputations: apigenin as a sleep and calm compound, chrysin as a testosterone booster sold in bodybuilding aisles. A 2024 review compared them systematically, and the human pharmacokinetic data explain the divergence better than the marketing does.
Key Takeaways
- Structurally they differ by one hydroxyl group at the 4′ position, which is enough to change receptor binding, metabolism and target profile.
- A 2024 Nutrients review found overlapping actions in three areas: cholesterol lowering, suppression of uric acid biosynthesis, and enhanced ketogenesis.
- They diverge from there. Chrysin downregulates alanine metabolism and pyrimidine synthesis. Apigenin raises endogenous anti-inflammatory lipids and vasoprotective metabolites.
- Chrysin’s aromatase-inhibition reputation rests almost entirely on in vitro work. A systematic review of 20 studies found only one human study among them.
- The decisive difference is absorption. A 400 mg oral dose of chrysin in seven volunteers produced peak plasma concentrations of just 3 to 16 nanograms per milliliter, with most of the dose recovered in feces.
One Hydroxyl Group Apart
Both are flavones, the subclass of flavonoids built on a 2-phenylchromen-4-one skeleton. Both carry hydroxyl groups at positions 5 and 7 on the A-ring. Apigenin adds one more at the 4′ position on the B-ring, and chrysin does not have it.
A single hydroxyl sounds trivial and is not. Hydroxyl position governs hydrogen bonding, which governs how a molecule fits an enzyme pocket or receptor site. It also governs which conjugation reactions the liver and gut perform, which in turn governs how much survives first-pass metabolism. Most of what follows traces back to that one difference.
Food sources differ accordingly. Apigenin is concentrated in chamomile, parsley and celery. Chrysin comes mainly from honey, propolis and passionflower.
Where They Overlap
The 2024 Nutrients review by Keefe and Puthanveetil is the most direct comparison available, drawing on two separate omics-based analyses by the authors’ own group alongside independent reports.[1]
Three shared properties emerged. Both showed cholesterol-lowering activity. Both suppressed uric acid biosynthesis, which lines up with separate structural work showing apigenin competitively inhibiting the urate transporter GLUT9.[2] And both enhanced ketogenesis, the metabolic shift toward ketone body production.
That overlap is exactly what shared structure predicts. Where the review gets useful is in what it found not shared.
Where They Diverge
Chrysin showed distinct effects on alanine metabolism and pyrimidine synthesis, both downregulated. Pyrimidine synthesis matters for rapidly dividing cells, which is why the review frames those actions as potentially relevant in metabolic disease and cancer contexts.
Apigenin’s distinct actions ran in a different direction: enhancing endogenous anti-inflammatory lipids and upregulating vasoprotective metabolites, which the authors connect to cardiovascular, renal and cerebrovascular applications.
Neither profile is inherently superior. They are different tools, and the review closes by noting that in vivo and translational validation is still required for both. That caveat is worth carrying forward, because omics profiling identifies changes in a system rather than demonstrating clinical outcomes.
The Aromatase Claim, Examined
Chrysin is sold primarily on one premise: that it inhibits aromatase, the enzyme converting androgens to estrogens, and therefore raises testosterone. The mechanism is real in a test tube.
A 2020 systematic review searched for every study of chrysin and aromatase activity and selected 20 relevant articles from 1,721 screened.[3] Nearly all showed chrysin inhibiting aromatase. Two important details sit inside that result: only one of the 20 studies was performed on humans, two were in rats, and everything else was in vitro. One study on endometrial stromal cells found no aromatase inhibition from chrysin or naringenin at all, which the authors attributed to differing assay methods and experimental conditions.
So the in vitro case is strong and the human case is close to absent. The reason for that gap is not mysterious.
The Pharmacokinetics That Settle It
In 2001, researchers gave seven healthy volunteers a 400 mg oral dose of chrysin and measured it in plasma, urine and feces.[4] The results are the single most useful data point in this comparison.
Peak plasma chrysin reached only 3 to 16 nanograms per milliliter. Plasma chrysin sulfate ran about 30-fold higher, meaning almost everything absorbed was immediately conjugated. Urinary chrysin totaled 0.2 to 3.1 mg against a 400 mg dose. Most of the dose appeared in feces as unchanged chrysin. The authors concluded chrysin has low oral bioavailability, driven by extensive metabolism plus efflux of metabolites back into the intestine.
Set that against the aromatase assays, which work at micromolar concentrations. A plasma level of 3 to 16 ng/mL is roughly 12 to 63 nanomolar. That is two to three orders of magnitude below the concentrations where inhibition was demonstrated, from a dose eight to sixteen times larger than a typical apigenin capsule.
Apigenin has a related but not identical problem. Human ADME work found free apigenin poorly absorbed, with metabolites equal to about 0.5 percent of intake recovered in urine. Crucially, glycoside forms did far better: chamomile tea’s apigenin-7-O-glucoside reached 34 percent urinary recovery and a parsley drink 11.2 percent.[5] Apigenin has a documented route to meaningfully better absorption through its glycosides. No equivalent finding exists for chrysin.
Which One, For What
If the goal is sleep, calm or anxiety, apigenin has the more relevant mechanism. Its binding at the benzodiazepine site of the GABA-A receptor is the reason chamomile has the reputation it does, and it is not a property chrysin shares to the same degree.
If the goal is raising testosterone by inhibiting aromatase, chrysin’s own human pharmacokinetic data argue against expecting an effect at any sane oral dose. Chrysin supplements are frequently sold with piperine on the theory that it overcomes the absorption limit, a workaround that has not been shown to close a thousandfold gap.
Neither compound has the trial base to justify strong claims. Between the two, apigenin has more human pharmacokinetic characterization, a documented high-absorption glycoside route, and a mechanism matched to what people actually take it for.
Bottom Line
Apigenin and chrysin differ by one hydroxyl group and share three documented actions: cholesterol lowering, uric acid suppression and enhanced ketogenesis. They diverge on alanine and pyrimidine metabolism for chrysin, and anti-inflammatory and vasoprotective lipids for apigenin. Chrysin’s aromatase reputation comes almost entirely from in vitro work that its own human study undercuts, with a 400 mg oral dose producing only 3 to 16 ng/mL in plasma. Apigenin is better characterized in humans and has a glycoside route to genuinely higher absorption that chrysin lacks.
Frequently Asked Questions
What is the difference between apigenin and chrysin?
Chemically they differ by a single hydroxyl group at the 4′ position, which apigenin has and chrysin does not. Apigenin comes mainly from chamomile, parsley and celery; chrysin from honey, propolis and passionflower. They share cholesterol-lowering, uric acid suppression and ketogenesis effects, but diverge on other metabolic targets.
Does chrysin actually raise testosterone?
The aromatase inhibition behind that claim comes almost entirely from in vitro studies. A systematic review of 20 studies found only one performed in humans. A human pharmacokinetic study gave 400 mg of chrysin orally and measured peak plasma levels of only 3 to 16 nanograms per milliliter, with most of the dose recovered unchanged in feces, far below the concentrations where aromatase inhibition was demonstrated.
Is apigenin or chrysin better absorbed?
Both are poorly absorbed in free form, but apigenin has a documented route around it. Human ADME research found free apigenin metabolites equivalent to about 0.5 percent of intake in urine, while apigenin glycosides reached 34 percent from chamomile tea and 11.2 percent from parsley. No comparable high-absorption route has been demonstrated for chrysin.
References
- Keefe P, Puthanveetil P. Compare and Contrast of the Cellular Actions of Related Flavonoids, Apigenin and Chrysin. Nutrients (2024). PMID 39683588
- Shen Z, Xu L, Wu T, et al. Structural basis for urate recognition and apigenin inhibition of human GLUT9. Nature Communications (2024). PMID 38866775
- Balam FH, Ahmadi ZS, Ghorbani A. Inhibitory effect of chrysin on estrogen biosynthesis by suppression of enzyme aromatase (CYP19): A systematic review. Heliyon (2020). PMID 32181408
- Walle T, Otake Y, Brubaker JA, Walle UK, Halushka PV. Disposition and metabolism of the flavonoid chrysin in normal volunteers. British Journal of Clinical Pharmacology (2001). PMID 11259985
- Borges G, Fong RY, Ensunsa JL, et al. Absorption, distribution, metabolism and excretion of apigenin and its glycosides in healthy male adults. Free Radical Biology and Medicine (2022). PMID 35452808
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
